Targanta Therapeutics
	Developer of innovative antibiotics to treat serious infections in the hospital and other institutional settings. The company develops antibiotics for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections.
	['biopharmaceutical ', 'skin infection', ' ', 'bone infection', ' antibiotic']
Paratek Pharmaceuticals
	Developer of products to treat infectious diseases. The company develops antibiotic and anti-infective products for blocking bacterial resistance. Its drug compounds include MK-2764/PTK 0796, a clinical stage tetracycline-derived antibiotic agent for the treatment of bacterial infections, including infections caused by resistant strains, such as MRSA.
	['', 'infectious disease', ' ', 'inflammatory disease', ' ', 'anti-infective product', '']
Inimex Pharmaceuticals
	Developer of innate defense regulators (IDRs) that trigger the body\'s innate defenses without causing inflammation. The company provides product which is active against normal and drug resistant bacteria and used to stimulate host innate immune defenses. Its products are used to treat infections in immune suppressed patients, antibiotic resistant hospital infections, and the management of inflammatory and cancer disease.
	['', 'developer of drung', '  ', 'innate immune defense', ' ', 'drug resistant bacteria', '']
NanoAntibiotics
	Developer of antibiotics to treat multi drug resistant bacterias. The company engages in the discovery, development and commercialization of antibiotics.
	['', 'antibiotic treatment', ' ', 'drug resistant bacteria', ' ', 'nano technology', '']
RQx Pharmaceuticals
	Developer of broad spectrum small molecule antibiotics. The company\'s antibiotics are developed for life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria.
	['', 'antibiotic developer', ' ', 'drug resistant infection', ' ', 'broad spectrum antibiotic', ' ', 'molecule antibiotics', ' ', 'life threatening infections', ' ', 'healthcare industry', '']
Mpex Pharmaceuticals
	Developer of therapies for antibiotic resistance. The company offers MP-376, a proprietary formula of levofloxacin that is developed clinically as a maintenance therapy for the prevention of bacterial exacerbations in patients with cystic fibrosis and chronic obstructive pulmonary diseases. It also provides inhibitors of bacterial multi-drug resistant efflux pumps, which are source of drug resistance in gram-negative pathogens, such as Pseudomonas aeruginosa and gram-positive pathogens, such as methicillin-resistant staphylococcus aureus. It has a strategic alliance with GlaxoSmithKline.
	['', 'antibiotic resistance therapy', ' ', 'gram-negative organism', ' antibiotic ', 'aerosol formulation', ' ', 'bacterial exacerbation', '']
Pinnacle Pharmaceuticals
	Developer of therapeutics for pain management, urology, antibiotics and oncology space by leveraging its supramolecular chemistry platform and drug formulation technology. The company also develops synergistic compounds for current antibiotic regimes to treat patients suffering from infections refractory to the current gold-standard and therapeutics for various infectious disease indications, including methicillin resistant staphylococcus aureus and vancomycin resistant enterococci.
	['', 'pain management', ' ', 'oncology space', ' ', 'supramolecular chemistry platform', ' ', 'drug formulation technology', ' ', 'synergistic compound', ' ', 'antibiotic regime', '']
Cempra Pharmaceuticals
	Developer of medicines for curing bacterial infections. The company discovers and develops differentiated medicines that cure bacterial infections. It develops antibiotics to treat multi-drug resistant bacterial infections.
	['', 'bacterial infection', ' ', 'infection treatment', ' ', 'infection medicine', ' ', 'drug resistant bacteria', ' ', 'bacterial antibiotics', '']
Cumbre Pharmaceuticals
	Developer of anti-infective products for the treatment of serious and life-threatening infections, particularly those caused by antibiotic resistant pathogens. The company discovers, develops and markets anti-infective products and antibacterial drug and multifunctional anti-infective drugs that target multiple inhibitory pathways.
	['', 'healthcare products', ' ', 'anti-infective products', ' ', 'antibacterial drug', '']
Arpida
	Developer of antimicrobial drugs for the treatment of infectious diseases. The companyâ€™s lead product is intravenous iclaprim, an antibiotic product that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus.
	['', 'antimicrobial drugs', ' antibiotic ', 'methicillin-resistant', ' ', 'staphylococcus aureus', '']
Achaogen
	Developer of antibacterial therapies for treating multi-drug resistant (MDR) infections. The company is focused on the discovery, development and commercialization of antibacterials to treat MDR gram-negative infections. Its lead product candidate is plazomcin, designed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE.
	['', 'bacterial infection', ' ', 'antibiotic resistant', ' ', 'antibacterial compound', ' ', 'drug-resistant', '']
Sequoia Pharmaceuticals
	Developer of drugs to combat drug-resistant viral infections.
	['', 'drug resistant infection', ' ', 'viral infection', '']
